Soligenix, Inc. (SNGX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SNGX SEC filings page.
This page shows Soligenix, Inc. (SNGX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Soligenix is still a development-stage business: FY2024 revenue was $119K , while research spending and financing supplied the operating base.
The cash pattern points to external financing dependence rather than self-funded operations: FY2025 operating cash flow was-$10.3M , closely matching the net loss of$11.1M , while financing supplied$10.4M . Losses are therefore translating into cash needs with little non-cash or working-capital cushion visible in the reported figures.
R&D rose from
FY2025 current ratio was 2.4x, up from 1.8x in FY2024, indicating improved short-term coverage. Liabilities were
Financial Health Signals
Soligenix, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Soligenix, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Soligenix, Inc. reported a net loss of $11.1M while operations used $10.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Soligenix, Inc. reported -$2.0M in net income in Q2 2026. This represents an increase of 26.4% from the same quarter a year earlier. Against the prior quarter it is up 29.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Soligenix, Inc. held $9.8M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Soligenix, Inc.'s ROE was -29.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 117.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 61.5 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Soligenix, Inc. invested $974K in research and development in Q2 2026. This represents a decrease of 41.9% from the same quarter a year earlier. Against the prior quarter it is down 45.3%.
Not reported for Q2 2026.
Not reported for Q2 2026.
SNGX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $974K-41.9% | $1.8M-8.2% | N/A | $1.6M+63.5% | $1.7M+234.6% | $1.9M+77.3% | N/A | $969K+17.3% |
| SG&A Expenses | $1.1M+3.5% | $1.1M+1.6% | N/A | $997K+11.2% | $1.1M-12.6% | $1.1M+6.1% | N/A | $897K-7.9% |
| Operating Income | -$2.1M+24.0% | -$2.9M+4.7% | N/A | -$2.6M-38.3% | -$2.8M-58.4% | -$3.0M-43.0% | N/A | -$1.9M-4.8% |
| Net Income | -$2.0M+26.4% | -$2.8M+4.3% | N/A | -$2.5M-47.2% | -$2.7M-64.3% | -$3.0M-54.1% | N/A | -$1.7M-3.4% |
| EPS (Basic) | -$0.12+85.4% | -$0.28+71.1% | $0.16+114.0% | -$0.58+25.6% | -$0.82+37.4% | -$0.97+66.7% | -$1.14-612.5% | -$0.78+69.5% |
| EPS (Diluted) | -$0.12 | -$0.28 | $0.16 | -$0.58 | -$0.82 | -$0.97 | -$1.14 | -$0.78 |
| Diluted Shares (Avg) | 16M | 10M | N/A | 4M | 3M | 3M | N/A | 2M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.
SNGX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.5M+82.3% | $6.9M-10.6% | $9.2M+3.0% | $11.3M+7.8% | $5.8M-41.6% | $7.7M-3.9% | $9.0M-8.5% | $10.5M-7.3% |
| Current Assets | $10.2M+91.2% | $6.6M-14.1% | $8.8M+0.2% | $10.9M+5.6% | $5.3M-44.9% | $7.6M-2.3% | $8.8M-7.1% | $10.3M-6.1% |
| Cash & Equivalents | $9.8M+92.5% | $6.0M-17.4% | $7.9M+1.5% | $10.5M+7.0% | $5.1M-45.8% | $7.3M+2.9% | $7.8M-7.4% | $9.8M-4.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.9M-2.0% | $3.8M-0.4% | $3.9M-18.7% | $3.7M-18.6% | $3.9M-38.6% | $3.8M-47.2% | $4.8M-33.4% | $4.5M-35.9% |
| Current Liabilities | $3.7M+1.2% | $3.6M | $3.7M-23.7% | $3.4M-24.5% | $3.6M-42.9% | N/A | $4.8M-21.2% | $4.5M-18.0% |
| Non-Current Liabilities | $182K-39.8% | $213K | $244K | $274K+2272.8% | $303K+562.3% | N/A | $0-100.0% | $12K-99.3% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | N/A |
| Total Equity | $6.6M+263.4% | $3.1M-20.7% | $5.3M+28.5% | $7.6M+28.0% | $1.8M-47.2% | $3.9M+407.3% | $4.1M+63.3% | $5.9M+40.6% |
| Retained Earnings | -$249.9M-4.3% | -$247.9M-4.5% | -$245.1M-4.7% | -$242.2M-4.8% | -$239.6M-4.5% | -$237.2M-4.2% | -$234.0M-3.7% | -$231.0M-3.2% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
SNGX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M+37.8% | -$2.4M-27.7% | -$2.7M-22.9% | -$2.9M-0.8% | -$2.7M-43.0% | -$1.8M-37.6% | -$2.2M-22.1% | -$2.9M-8.3% |
| Stock-Based Compensation | N/A | $121K+90.6% | N/A | N/A | N/A | $64K+6.1% | N/A | $57K-13.4% |
| Capital Expenditures | N/A | N/A | $2K | $608 | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$2.7M | -$2.9M | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | -$2K | -$608 | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $5.5M+905.9% | $451K-66.0% | $158K-35.0% | $8.4M+153.9% | $546K-87.1% | $1.3M+14831.6% | $243K+625.9% | $3.3M+1979.1% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Dividends Paid, Share Buybacks.
SNGX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -29.9%+117.8pp | -91.4%-15.7pp | N/A | -33.3%-4.3pp | -147.7%-100.3pp | -75.7%+173.6pp | N/A | -29.0%+10.4pp |
| Return on Assets | -18.9%+28.0pp | -40.8%-2.7pp | N/A | -22.4%-6.0pp | -46.9%-30.2pp | -38.1%-14.3pp | N/A | -16.4%-1.7pp |
| Current Ratio | 2.77+1.3x | 1.81 | 2.39+0.6x | 3.18+0.9x | 1.47-0.1x | N/A | 1.82+0.3x | 2.28+0.3x |
| Debt-to-Equity | 0.58-1.6x | 1.24+0.3x | 0.75+0.7x | 0.49-0.3x | 2.15+0.3x | 0.99-8.5x | 0.00-0.4x | 0.77+0.4x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Soligenix, Inc. SNGX | FY2025 | N/A | -$11.1M | N/A | $7.7M | — |
| XTL Biopharmaceuticals Ltd. XTLB | FY2025 | $451K | N/A | N/A | $4.7M | — |
| Leap Therapeutics, Inc. LPTX | FY2025 | N/A | $5.0M | N/A | $116.1M | — |
| Sensei Biotherapeutics, Inc. SNSE | FY2025 | N/A | -$21.1M | N/A | $18.6M | — |
| Moleculin Biotech, Inc. MBRX | FY2025 | $0 | $33.6M | N/A | $8.4M | — |
| Mustang Bio, Inc. MBIO | FY2025 | N/A | -$1.9M | N/A | $3.1M | — |
Where Soligenix, Inc. Ranks
Frequently Asked Questions
Is Soligenix, Inc. profitable?
No, Soligenix, Inc. (SNGX) reported a net income of -$11.1M in fiscal year 2025.
What is Soligenix, Inc.'s return on equity (ROE)?
Soligenix, Inc. (SNGX) has a return on equity of -209.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Soligenix, Inc.'s free cash flow?
Soligenix, Inc. (SNGX) recorded an outflow of $10.3M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Soligenix, Inc.'s operating cash flow?
Soligenix, Inc. (SNGX) recorded an outflow of $10.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Soligenix, Inc.'s total assets?
Soligenix, Inc. (SNGX) had $9.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Soligenix, Inc.'s capital expenditures?
Soligenix, Inc. (SNGX) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Soligenix, Inc. spend on research and development?
Soligenix, Inc. (SNGX) invested $7.5M in research and development during fiscal year 2025.
What is Soligenix, Inc.'s current ratio?
Soligenix, Inc. (SNGX) had a current ratio of 2.39 as of fiscal year 2025, which is generally considered healthy.
What is Soligenix, Inc.'s debt-to-equity ratio?
Soligenix, Inc. (SNGX) had a debt-to-equity ratio of 0.75 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Soligenix, Inc.'s return on assets (ROA)?
Soligenix, Inc. (SNGX) had a return on assets of -120.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Soligenix, Inc.'s P/E ratio?
Soligenix, Inc. (SNGX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Soligenix, Inc.'s price-to-sales ratio?
Soligenix, Inc. (SNGX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $7.7M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Soligenix, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Soligenix, Inc. (SNGX) held $7.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.3M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Soligenix, Inc.'s Piotroski F-Score?
Soligenix, Inc. (SNGX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Soligenix, Inc.'s earnings high quality?
Soligenix, Inc. (SNGX) reported a net loss of $11.1M while operations used $10.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.